# Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

> **NCT07250477** · PHASE2 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 56 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIC
- Non-small Cell Lung Cancer Stage IV
- Non Small Cell Lung Cancer
- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Unresectable

## Interventions

- **DRUG:** Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT07250477
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2036-05
- **Final completion:** 2036-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07250477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07250477, "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07250477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*